IMMUNITY IN PATIENTS WITH TROPHOBLASTIC DISEASE
https://doi.org/10.17650/1994-4098-2009-0-1-2-63-67
Abstract
The investigation included 39 female patients with different forms of trophoblastic disease whose immunity was studied by the cur- rently available procedures. The patients were divided into 2 groups. Group 1 comprised 29 patients with a history of hydatidiform mole, who received no chemotherapy (CT) since an analysis of the data did not show the presence of a trophoblastic tumor. Group 2 consisted of 10 patients with a verified trophoblastic tumor who received CT with various drugs. The patients with trophoblastic disease were found to have some abnormal immunological parameters; however, they differ little in patients with the malignant and benign course of the disease and cannot serve as a prognostic factor. Activated lymphocytes were substantially increased in both groups, suggesting an active immune response to antigen-foreign cells expressing along with parenteral antigens. The patients with hydatidiform mole have the sign to be further studied, that is a reduction in the count of СD25-positive Т lymphocytes, pos- sibly, suppressor cells.
About the Authors
B. O. Toloknov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. G. Slavina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Z. G. Kadagidze
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. P. Laktionov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Е. Е. Makhova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. I. Chertkova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
I. V. Markina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Григорова Т.М. Трофобластическая болезнь. М.: Медицина, 1985.
2. Nagymanyoki Z., Callahan M.J., Parast M.M. et al. Immune cell Profiling in normal pregnancy, partial and complet molar pregnancy. Gynecjl Omcol 2007;107(2):292—7.
3. Wang X., Fu S., Freedman R.S. et al. Immunobiology of gestational trophoblastic diseases. Int J Gynecol Cancer 2006;16(4):1500—15.
4. Krishnan L., Kinsky B., Chaounat G. et al. Suppression of local and systemic GvHR by supernatants from choriocarci- noma cell lines. Cell Immunol 1993;150(2):376—84.
5. Krishnan L., Sads S., Raghupathy R. Characterization of an immunosupressiv factor secreted by a human trophoblastderived choriocfarcinoma cell line. Cell Immunol 1995;162(2):295—308.
6. Boyum A. Separation of blood leuco- cytes. Granulicytes and lymphocytes. Tiss antigen 1974;4:269—74.
7. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assay. J Immunol Method 1983;65(1): 55—60.
Review
For citations:
Toloknov B.O., Slavina E.G., Kadagidze Z.G., Laktionov K.P., Makhova Е.Е., Chertkova A.I., Markina I.V. IMMUNITY IN PATIENTS WITH TROPHOBLASTIC DISEASE. Tumors of female reproductive system. 2009;(1-2):63-67. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-1-2-63-67
Views:
585
Email this article 